709639-84-9

Upstream product

• 6299-25-8 4,6-Dichloro-2-(methylthio)pyrimidine 
• 100-46-9 benzylamine 

Downstream Products

• 1337567-00-6 benzyl-(6-chloro-2-methanesulfonylpyrimidin-4-yl)amine 
• 1337567-01-7 C₁₁H₁₂ClN₅ 
• 1337567-02-8 C₂₅H₁₇BrCl₂F₃N₅ 
• 1337567-03-9 C₂₅H₁₆Cl₂F₃N₅ 
• 1337567-04-0 C₃₂H₂₄ClF₃N₆ 
• 1337567-05-1 C₃₂H₂₃BrClF₃N₆ 
• 1337567-06-2 C₃₆H₂₈ClF₃N₈ 
• 1337567-09-5 C₂₅H₁₇BrClF₄N₅ 
• 1337567-10-8 C₂₅H₁₆ClF₄N₅ 
• 1337567-11-9 C₃₂H₂₄F₄N₆ 
• 1337567-12-0 C₃₂H₂₃BrF₄N₆ 
• 1337567-13-1 C₃₈H₂₉F₄N₇O 
• 1337567-15-3 C₂₅H₁₈BrClF₃N₅ 
• 1337567-16-4 C₂₅H₁₇ClF₃N₅ 

Relevant academic research and scientific papers

Discovery of 2-(cyclohexylmethylamino)pyrimidines as a new class of reversible valosine containing protein inhibitors

Valosine-containing protein (VCP), also known as p97 or cdc48 in yeast, is a highly abundant protein belonging to the AAA ATPase family involved in a number of essential cellular functions, including ubiquitin-proteasome mediated protein degradation, Golgi reassembly, transcription activation, and cell cycle control. Altered expression of VCP has been detected in many cancer types sometimes associated with poor prognosis. Furthermore, VCP mutations are causative of some neurodegenerative disorders. In this paper we report the discovery, synthesis, and structure-activity relationships of substituted 2-aminopyrimidines, representing a new class of reversible VCP inhibitors. This class of compounds, identified in a HTS campaign against recombinant VCP, has been progressively expanded and manipulated to increase biochemical potency and gain cellular activity.

The first example of the Fischer-Hepp type rearrangement in pyrimidines

A N-nitroso moiety can be used for the activation of chloropyrimidines toward a nucleophilic substitution reaction with amines. The subsequent treatment of the obtained products with aq H2SO4 can lead to either N-denitrosation to obtain 4,6-pyrimidinediamines or to a Fischer-Hepp type rearrangement to obtain 5-nitroso-4,6-pyrimidinediamines. It was found that the outcome of the reaction strongly depends on the structure of the pyrimidines. Activation of the pyrimidine ring by three groups with a positive mesomeric effect is crucial for the intramolecular nitroso group migration.

SOLUBLE GUANYLATE CYCLASE ACTIVATORS

The invention relates to compounds having the structure of Formula (I) and pharmaceutically acceptable salts thereof, which are soluble guanylate cyclase activators. The compounds are capable of modulating the body's production of cyclic guanosine monophosphate ("cGMP") and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.